Catalent Pharma Solutions, today announced the introduction of its Peel-ID™ label, a new standard for clinical supply labeling that helps to reduce the risk of patients receiving the incorrect medication at clinical sites. Learn More.
Somerset, N.J. – May 19, 2016 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health products and global clinical supply services, today announced the introduction of its Peel-ID™ label, a new standard for clinical supply labeling that helps to reduce the risk of patients receiving the incorrect medication at clinical sites.
The patent pending clinical label comprises a permanent portion, and a peel-off label containing the patient kit identifier, which can be removed by site personnel and affixed elsewhere on the patient kit to better facilitate storage, inventory management and quick retrieval. Peel-ID labels are designed and printed in-house by Catalent and are available in a variety of standard sizes and designs to fit most patient kits.
The Peel-ID label was developed in response to some sites manually writing kit identification numbers on an unlabeled side of a package, because the label is obscured due to the way the kits are stored. With a Peel-ID label, the risk of human error resulting from the incorrect kit being pulled from inventory due to illegible handwriting or incorrectly transposed numbers is greatly reduced.
“Our clinical site liaisons recognized the potential for harm from this practice and engaged our employees to develop an innovative and practical solution,” said Esther Sadler-Williams, Global Director Strategic Development and Innovation at Catalent. “Peel-ID will now be our standard recommendation to customers for all patient kits packaged by Catalent, reducing risks to patient safety.”
“The innovative Peel-ID label gives clinical sites increased flexibility in their storage options whilst being confident that an integral, approved label can be used on any surface of the kit,” added Dr. Samantha Carmichael, Lead Pharmacist Clinical Trials, Clinical Research & Development, NHS Greater Glasgow & Clyde. “This could streamline the dispensing process for patients at sites that hold a lot of stock, and those that undertake a manual transcription process can be confident in a reduced risk of errors.”
+44 (0)7580 041073
+44 (0) 161 728 5880
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and global clinical supply services. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com.
About Catalent Clinical Supply
With facilities in the US, UK, Germany, Singapore and China, and an extended network of over 50 audited depots, Catalent’s clinical supply services team has the capability and expertise to handle a broad range of international compliance and distribution requirements, that can help to expedite clinical trials and ensure that customers are reliably supplied where and when needed around the globe.